SOURCE: Medivation

Medivation

February 22, 2012 17:26 ET

Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012

SAN FRANCISCO, CA--(Marketwire - Feb 22, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end financial results and provide a general business update on Wednesday, February 29, 2012 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2011 will be released after markets close on February 29, 2012.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at www.medivation.com.

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Sr. Director, Investor Relations
    (650) 218-6900